PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants
Abstract We assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the Breast Cancer Association Consortium (BCAC)....
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Portfolio
2023-05-01
|
| Col·lecció: | npj Breast Cancer |
| Accés en línia: | https://doi.org/10.1038/s41523-023-00546-x |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
